Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.
Naomi Dempsey, MD, discusses her poster presented at the 2023 San Antonio Breast Cancer Symposium analyzing the correlation of the Breast Cancer Index and patient risk factors.
Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.
The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.
Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.
Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Prospective models show a drop in the cost of running sentinel lymph node assessments when artificial intelligence is used.
Adding ribociclib to endocrine therapy shows efficacy and tolerability for those with hormone receptor–positive, HER2-negative advanced breast cancer, even in older patients.
In an interview with Targeted Oncology, Neeraj Agarwal, MD, discussed findings from the TITAN trial which were presented at ESMO 2023.
In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.
In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.
Results from a phase 1/2a trial showed that plixorafenib had potential regarding safety and efficacy in BRAF-mutated solid tumors, especially in primary central nervous system tumors.
The combination of olaptesed pegol, bevacizumab, and radiotherapy showed an improvement in overall survival among patients with glioblastoma, according to findings from a phase 1/2 study.
Carlos Rojas, MD, discusses preliminary findings from a phase 1 trial which of MK-1084 alone and with pembrolizumab in patients with advanced solid tumors and metastatic non–small cell lung cancer.
Julia Rotow, MD, discussed emerging data on upfront therapies for patients with lung cancer harboring EGFR mutations in a presentation at the 18th Annual New York Lung Cancers Symposium.
An analysis, based on data from the JAVELIN 100 Bladder trial, found the NCCN/FACT Bladder Symptom Index-18 for assessing quality-of-life in patients with advanced urothelial carcinoma to be reliable and valid.
Arnab Basu, MD, MPH, FACP, discusses molecular residual disease-guided adjuvant therapy in patients with renal cell carcinoma, highlighting the rationale and goals of the MRD gate RCC clinical trial.
Survival benefits for immunotherapy doublets outweigh chemotherapy alone in advanced stage PD-L1-negative non-small cell lung cancer.
Hossein Borghaei, MS, DO, provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium.
The early adoption of ctDNA into the clinical workflow improves time to treatment, survival, and monitoring for patients undergoing molecular-based therapy.
Early trials are exploring the benefit of chimeric antigen receptor T-cell therapy in advanced renal cell carcinoma.
In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.
The RCC Cancer Immunity Cycle may inform the treatment and development of novel therapies in renal cell carcinoma moving forward.
An expert discussed how the use of circulating tumor DNA in patients with RCC may help guide whether treatment should be intensified or deescalated.
For many immune-related adverse events, steroids are used as frontline treatment. However, it remains unclear if steroids allow for preservation of the antitumor immune response, resulting in the need for more options for patients with cancer.